G. Wilding
Molecular Biology · 2006–2016
A researcher in the Science corpus: 7 papers; trusts 2 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 25 citations into it
- Physiology — 15 citations into it
Whom G. Wilding trusts
Their strongest outbound trust, strongest first, inferred from their citations.
- J. Campisi (in Physiology)
- F. d’Adda di Fagagna (in Physiology)
Papers from G. Wilding's perspective
Ordered by how strongly the researchers G. Wilding trusts endorse each paper. Same corpus, a different order for every researcher.
- Senescent fibroblasts promote epithelial cell growth and tumorigenesis: A link between cancer and aging (Proceedings of the National Academy of Sciences of the United States of America)
- Chemokine signaling via the CXCR2 receptor reinforces senescence. (Cell)
- Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. (Cell)
- Tumour biology: Senescence in premalignant tumours (Nature)
- Living on a break: cellular senescence as a DNA-damage response (Nature Reviews. Cancer)
- Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas (Nature)
- Reversal of human cellular senescence: roles of the p53 and p16 pathways (EMBO Journal)
- BRAFE600-associated senescence-like cell cycle arrest of human naevi (Nature)
- Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. (Cell)
- Cellular senescence: when bad things happen to good cells (Nature reviews. Molecular cell biology)
Their papers
- Therapy-induced senescence in cancer. (2010) — 768 citations
- Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. (2006) — 1,640 citations
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma (2009) — 2,196 citations
- Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. (2016) — 1,381 citations
- Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. (2008) — 2,212 citations
- Sunitinib in patients with metastatic renal cell carcinoma. (2006) — 1,248 citations
- Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. (2006) — 924 citations